Swiss pharmaceuticals and life sciences group Lonza said Thursday it had bought US capsule maker Capsugel for $5.5 billion as it focuses more on health care.
Swiss pharmaceuticals and life sciences group Lonza said Thursday it had bought US capsule maker Capsugel for $5.5 billion as it focuses more on health care.